parecoxib
Small moleculeexperimental
Parecoxib, sold under the brand name Dynastat among others, is a water-soluble and injectable prodrug of valdecoxib. Parecoxib is a COX2 selective inhibitor. It is injectable. It is approved in the European Union for short term perioperative pain control. — Wikipedia
Clinical trial activity
53 trials · 47 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
11
Phase 3
9
Phase 4
26
Earliest trial started Apr 1, 2002 (NCT00139646)
Timeline
Indications
Approved for
Studied for
- Analgesia · Phase 4
- Analgesics, Opioid · Phase 4
- Anemia, Sickle Cell · Phase 3
- Anesthesia · Phase 4
- Anterior Cruciate Ligament Injuries · Phase 4
- Colectomy · Phase 3
- Colic · Phase 3
- Drugs, Investigational · Phase 4
- Emergence Delirium · Phase 4
- Epigenomics · Phase 4
- Gastrointestinal Neoplasms · Phase 4
- General Surgery · Phase 4
- Gynecologic Surgical Procedures · Phase 4
- Healthy Volunteers · Phase 4
- Hemangioma · Phase 4
- HIV Infections · Phase 4
- Hyperalgesia · Phase 4
- Inflammation · Phase 4
- Knee Injuries · Phase 4
- Neurosurgery · Phase 4
- Pain · Phase 4
- Pain Threshold · Phase 4
- Pancreatitis · Phase 4
- Perioperative Care · Phase 4
- Pharyngitis · Phase 2
- Postoperative Complications · Phase 2/Phase 3
- Postoperative Pain · Phase 4
- Rib Fractures · Phase 3
- Shoulder Pain · Phase 2
- Urological Manifestations · Phase 2
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
Parecoxib is hydrolyzed by hepatic carboxyesterases to its active form, valdecoxib. Valdecoxib selectively binds to and inhibits COX-2. This prevents the conversion of arachidonic acid into prostaglandins, which are involved in the regulation of pain, inflammation, and fever. It does not inhibit COX-1 at therapeutic concentrations and, therefore, does not interfere with blood coagulation.
Chemistry & pharmacology
Loading structure…
SMILES
CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1- Mol. weight
- 370.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL1206690 ↗
- WikipediaParecoxib ↗
- ChEMBLCHEMBL296913 ↗
Also known as
- dynastat
- dynastat
- dynastat
- dynastat
- dynastat
- dynastat
- n-(((5-methyl-3-phenylisoxazol-4-yl)-phenyl)sulfonyl)propanamide
- n-(((5-methyl-3-phenylisoxazol-4-yl)-phenyl)sulfonyl)propanamine, sodium salt
- n-(((me-p)-p)s)p
- paracoxib
- parecoxib
- parecoxib
- parecoxib
- parecoxib
- parecoxib
- parecoxib
- parecoxib
- parecoxib
- parecoxib
- parecoxib
- parecoxib sodium
- parecoxib sodium
- parecoxib sodium
- parecoxib sodium
- parecoxib sodium
- sc-69124
- sc-69124
- sc-69124a
- sc-69124a
- xapit
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07154446 | Phase 4 | Oct 1, 2025 | University of Malaya |
| NCT07116304 | N/A | Aug 1, 2025 | Oman Medical Board Specialty (OMSB) |
| NCT06579274 | Phase 2 | Jan 1, 2025 | CZECRIN - Czech Clinical Research Infrastructure Network, Masaryk University, University Hospital Brno |
| NCT06600282 | Phase 4 | Oct 1, 2024 | Yung Shin Pharm. Ind. Co., Ltd. |
| NCT06315920 | Phase 3 | May 1, 2024 | Government of Oman, Oman Medical Board Specialty (OMSB) |
| NCT06437886 | N/A | Apr 22, 2024 | Chinese Academy of Medical Sciences |
| NCT06304181 | N/A | Mar 15, 2024 | Zhejiang University |
| NCT06140238 | Phase 4 | Sep 10, 2023 | Rajavithi Hospital, Bangkok |
| NCT05757388 | N/A | Mar 28, 2023 | KhonKaen University |
| NCT05681429 | N/A | Jan 1, 2023 | Fresenius, University of Malaya |
| NCT05150431 | Phase 4 | Dec 15, 2021 | National Taiwan University |
| NCT04314505 | Phase 4 | Feb 20, 2020 | Taipei Veteran General hospital |
| NCT05393414 | N/A | Nov 25, 2019 | University of Puerto Rico |
| NCT04034836 | Phase 4 | Sep 1, 2019 | Capital Medical University |
| NCT04847024 | N/A | Jul 1, 2019 | Saint Thomas Hospital, Panama |
| NCT03915561 | Phase 2 | Mar 1, 2019 | Tzu Chi University |
| NCT03704623 | N/A | Jan 15, 2019 | Mansoura University |
| NCT03823846 | N/A | Nov 1, 2017 | Zhejiang University |
| NCT03135795 | Phase 4 | Feb 6, 2017 | Huazhong University of Science and Technology |
| NCT02964403 | Phase 4 | Dec 1, 2016 | Jiao Tong University |
Showing 20 of 53 trials
Page 1 / 3
Organizations
Research & Development (47)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 12 | 9 | 3 | 2002 |
| Sun Yat-Sen University | Academic/Hospital | 4 | 4 | 2 | 2009 |
| Tsinghua University | Academic/Hospital | 3 | 3 | 1 | 2013 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 2 | 1 | 2010 |
| Oman Medical Board Specialty (OMSB) | Government | 2 | 2 | 2 | 2024 |
| Ruhr University Bochum | Academic/Hospital | 2 | 2 | 1 | 2004 |
| University of Malaya | Academic/Hospital | 2 | 2 | 2 | 2023 |
| University of Oslo | Academic/Hospital | 2 | 2 | 1 | 2004 |
| Zhejiang University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Aristotle University of Thessaloniki | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Asklepieion General Hospital | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Baerum Hospital | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Chang Gung University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Chiangmai University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
| CZECRIN - Czech Clinical Research Infrastructure Network | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Fresenius | For profit | 1 | 0 | 1 | 2023 |
| Gennimatas Hospital, Athens | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Government of Finland | Government | 1 | 0 | 1 | 2004 |
47 organizations
Page 1 / 3